Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models

New therapies are required for patients with non-small cell lung cancer (NSCLC) for which the current standards of care poorly affect the patient prognosis of this aggressive cancer subtype. In this preclinical study, we aim to investigate the efficacy of Fingolimod, a described inhibitor of sphingo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rupp, Tristan, Debasly, Solène, Genest, Laurie, Froget, Guillaume, Castagné, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330228/
https://www.ncbi.nlm.nih.gov/pubmed/35897763
http://dx.doi.org/10.3390/ijms23158192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330228/
https://www.ncbi.nlm.nih.gov/pubmed/35897763
http://dx.doi.org/10.3390/ijms23158192

Ejemplares similares